Articles related to Cardiology, Interventional

The new recommendations include continuing antiplatelet therapy for patients with a baseline indication for it, starting dual antiplatelet therapy for patients with confirmed ACS, and adding prophylactic-dose LMWH for patients on antiplatelet therapy for a previous stroke.

A new study suggests that vitamin D supplementation may reduce the risk of major cardiovascular events in older adults. The findings of this study warrant further investigation to determine the optimal dose and duration of vitamin D supplementation for cardiovascular disease prevention.

The FDA-approved LODOCO is anticipated to significantly advance cardiovascular treatment, reducing cardiac events by 31% in established cardiovascular disease patients. Read about the innovative research that has led to this breakthrough in patient care.

Findings from this trial may reshape how physicians perceive and prescribe testosterone-replacement therapy for middle-aged and older men with hypogonadism, with no substantial rise in major adverse cardiac events reported.

Despite the demonstrated benefits of the recommended quadruple therapy for heart failure, its cost-effectiveness is highly sensitive to drug pricing, necessitating more thorough scrutiny and potential policy interventions to ensure equitable patient access.

It’s clear that addressing the carbon footprint in intensive care units (ICUs) is an important area of concern in tackling the climate crisis. As ICUs are a carbon hotspot, various measures can be taken to reduce their impact on the environment without compromising patient care.